Literature Analysis Report of Clinical Randomized Controlled Trials of proprietary Chinese Medicines(2021)
- VernacularTitle:中成药临床随机对照试验文献分析报告(2021)
- Author:
Dehui PENG
1
,
2
;
Yazi ZHANG
;
Haiyin HU
;
Junhua ZHANG
;
Zhaochen JI
;
Hui WANG
Author Information
- Keywords: Chinese patent medicine; Randomized controlled trial; Clinical research; Evidence; Evidence-based medicine
- From: World Science and Technology-Modernization of Traditional Chinese Medicine 2024;26(1):109-118
- CountryChina
- Language:Chinese
- Abstract: Objective This study aims to summarize and evaluate clinical evidence of randomized controlled trial(RCT)of Chinese patent medicine published in 2021 and providing reasonable suggestions.Methods The collection literatures of Evidence Database System of TCM(EVDS)was main source,and CNKI,Wan Fang Data,VIP,SinoMed,Cochrane Library,PubMed,and EMbase databases were supplement.Obtaining the RCT of Chinese patent medicine published in 2021,and to analyze and evaluate their characteristics and methodological quality.Results 2215 RCTs of Chinese patent medicine(2206 in Chinese/9 in English)were included,which involving 237,379 patients,26 types of diseases,and 750 types of proprietary Chinese medicines(619 types of oral Chinese patent medicine,91 types of Chinese injections,and 40 types of topical Chinese patent medicine).The circulatory system diseases,respiratory system diseases and neurological diseases was highlight research area.The most number of diseases were ischemic Stroke,coronary heart disease,and angina pectoris.The sample size between 30 and 8,000 cases,and the case sources were mainly single-center.Methodologically,the implementation of allocation concealment and blinding remained unappreciated.Conclusion The number of RCTs publication increased in 2021 compared with 2020,more studies pay attention to neurological disease research,and quality control and standardized management during study design and implementation still need to be improved.
